Last reviewed · How we verify

intra-vitreal injection of Ranibizumab

Ain Shams University · FDA-approved active Small molecule

intra-vitreal injection of Ranibizumab is a VEGF-A inhibitor (monoclonal antibody fragment) Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).

Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.

Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).

At a glance

Generic nameintra-vitreal injection of Ranibizumab
SponsorAin Shams University
Drug classVEGF-A inhibitor (monoclonal antibody fragment)
TargetVEGF-A (Vascular Endothelial Growth Factor A)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Ranibizumab blocks VEGF-A, a key driver of pathological neovascularization and increased vascular permeability in retinal diseases. By neutralizing VEGF-A, it reduces fluid leakage, prevents abnormal vessel formation, and slows or halts disease progression in conditions affecting the retina and choroid. The intravitreal injection route delivers the drug directly to the posterior segment of the eye for local therapeutic effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about intra-vitreal injection of Ranibizumab

What is intra-vitreal injection of Ranibizumab?

intra-vitreal injection of Ranibizumab is a VEGF-A inhibitor (monoclonal antibody fragment) drug developed by Ain Shams University, indicated for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).

How does intra-vitreal injection of Ranibizumab work?

Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.

What is intra-vitreal injection of Ranibizumab used for?

intra-vitreal injection of Ranibizumab is indicated for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central), Diabetic retinopathy, Myopic choroidal neovascularization.

Who makes intra-vitreal injection of Ranibizumab?

intra-vitreal injection of Ranibizumab is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

What drug class is intra-vitreal injection of Ranibizumab in?

intra-vitreal injection of Ranibizumab belongs to the VEGF-A inhibitor (monoclonal antibody fragment) class. See all VEGF-A inhibitor (monoclonal antibody fragment) drugs at /class/vegf-a-inhibitor-monoclonal-antibody-fragment.

What development phase is intra-vitreal injection of Ranibizumab in?

intra-vitreal injection of Ranibizumab is FDA-approved (marketed).

What are the side effects of intra-vitreal injection of Ranibizumab?

Common side effects of intra-vitreal injection of Ranibizumab include Conjunctival hemorrhage, Eye pain, Floaters, Intraocular pressure elevation, Endophthalmitis, Retinal detachment.

What does intra-vitreal injection of Ranibizumab target?

intra-vitreal injection of Ranibizumab targets VEGF-A (Vascular Endothelial Growth Factor A) and is a VEGF-A inhibitor (monoclonal antibody fragment).

Related